Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 5/20 | 0.39 |
| ▸ | CCND1 | P24385 | 5/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
| ▸ | MC5R | P33032 | 2/20 | 0.39 |
| ▸ | MC3R | P41968 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406656 | 0.90 | GPR84 (0.44) | TACR2CDK4CCND1MC4RMC5R | |
| SCHEMBL2405096 | 0.90 | TACR2 (0.43) | TACR2CDK4CCND1MC4RMC5R | |
| SCHEMBL1968625 | 0.89 | TACR2 (0.53) | TACR2CDK4CCND1MC4RMC5R | |
| SCHEMBL2405431 | 0.89 | SLC6A4 (0.39) | TACR2CDK4CCND1SLC6A4MC4R | |
| SCHEMBL2409802 | 0.88 | HTR6 (0.46) | TACR2CDK4CCND1CDK2 | |
| SCHEMBL2405302 | 0.85 | TACR2 (0.43) | TACR2CDK4CCND1SLC6A4MC4R | |
| SCHEMBL2405988 | 0.85 | HTR1A (0.43) | TACR2SLC6A4OPRM1 | |
| SCHEMBL1969998 | 0.83 | CDK4 (0.51) | TACR2CDK4CCND1MC4RMC5R | |
| SCHEMBL2403866 | 0.83 | KMT2A (0.50) | CYP2D6CYP2C9 | |
| SCHEMBL1972300 | 0.82 | CDK4 (0.49) | TACR2CDK4CCND1MC4RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | TACR2 90/4885CDK4 3031/4885CCND1 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.